Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma.

Friebe A, Horn M, Schmidt F, Janssen G, Schmid-Wendtner MH, Volkenandt M, Hauschild A, Goldsmith CH, Schaefer M.

Psychosomatics. 2010 Nov-Dec;51(6):466-73. doi: 10.1176/appi.psy.51.6.466.

PMID:
21051677
2.

Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.

Heinze S, Egberts F, Rötzer S, Volkenandt M, Tilgen W, Linse R, Boettjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Hinzpeter A, Hauschild A, Schaefer M.

J Immunother. 2010 Jan;33(1):106-14. doi: 10.1097/CJI.0b013e3181b8bdb9.

PMID:
19952950
3.
4.

Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha.

Schaefer M, Horn M, Schmidt F, Schmid-Wendtner MH, Volkenandt M, Ackenheil M, Mueller N, Schwarz MJ.

Brain Behav Immun. 2004 Nov;18(6):555-62.

PMID:
15331126
5.

Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment.

Beratis S, Katrivanou A, Georgiou S, Monastirli A, Pasmatzi E, Gourzis P, Tsambaos D.

J Psychosom Res. 2005 Jan;58(1):15-8.

PMID:
15771865
6.

Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study.

Lieb K, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Janssen G, Schaefer M.

Eur Psychiatry. 2006 Apr;21(3):204-10.

PMID:
16632167
7.

Depression in hospitalized patients with malignant melanoma treated with interferon-alpha-2b: primary to induced disorders.

Navinés R, Gómez-Gil E, Puig S, Baeza I, De Pablo J, Martín-Santos R.

Eur J Dermatol. 2009 Nov-Dec;19(6):611-5. doi: 10.1684/ejd.2009.0787. Epub 2009 Aug 26.

PMID:
19709980
8.

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M.

J Clin Oncol. 2004 Jan 1;22(1):53-61. Epub 2003 Dec 9.

PMID:
14665609
9.

[Tolerance and feasibility of adjuvant treatment of stage II malignant melanoma with high-dose interferon-alpha].

Bédane C, Le Brun V, Boulinguez S, Berdah JF, Bouyssou ML, Delpuget N, Bernard P, Tubiana-Mathieu N, Bonnetblanc JM.

Ann Dermatol Venereol. 1999 Feb;126(2):142-6. French.

10.

Intermediate dose recombinant interferon-alpha as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon.

Ascierto PA, Daponte A, Parasole R, Perrone F, Caracò C, Melucci M, Palmieri G, Napolitano M, Mozzillo N, Castello G.

Cancer. 2000 Oct 1;89(7):1490-4.

PMID:
11013362
11.

Promoter polymorphisms of the interferon-alpha receptor gene and development of Interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings.

Yoshida K, Alagbe O, Wang X, Woolwine B, Thornbury M, Raison CL, Miller AH.

Neuropsychobiology. 2005;52(2):55-61. Epub 2005 Jun 29.

PMID:
15990456
12.

Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein.

Humpoliková-Adámková L, Kovarík J, Dusek L, Lauerová L, Boudný V, Fait V, Fojtová M, Krejcí E, Kovarík A.

Eur J Cancer. 2009 May;45(7):1315-23. doi: 10.1016/j.ejca.2009.01.009. Epub 2009 Feb 14.

PMID:
19232485
13.

Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study.

Pavlović Z, Delić D, Marić NP, Vuković O, Jašović-Gašić M.

Psychiatr Danub. 2011 Dec;23(4):370-7.

14.

Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.

Muggiano A, Mulas C, Fiori B, Liciardi G, Pintus M, Tanca L, Tedde A, Turno R, Desogus A.

Melanoma Res. 2004 Apr;14(2):S1-7.

PMID:
15057049
15.

Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma.

Friebe A, Schwarz MJ, Schmid-Wendtner M, Volkenandt M, Schmidt F, Horn M, Janssen G, Schaefer M.

J Immunother. 2007 Apr;30(3):333-7.

PMID:
17414324
16.

Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.

Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, Bedikian AY.

Cancer. 2004 Aug 1;101(3):596-603.

17.

Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment.

Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, Miller AH.

Biol Psychiatry. 2003 Nov 1;54(9):906-14.

PMID:
14573318
18.

Self-efficacy for coping with cancer in melanoma patients: its association with physical fatigue and depression.

Albrecht K, Droll H, Giesler JM, Nashan D, Meiss F, Reuter K.

Psychooncology. 2013 Sep;22(9):1972-8. doi: 10.1002/pon.3238. Epub 2013 Jan 3.

PMID:
23288588
19.

Health-related quality of life before and during adjuvant interferon-α treatment for patients with malignant melanoma (DeCOG-trial).

Ziefle S, Egberts F, Heinze S, Volkenandt M, Schmid-Wendtner M, Tilgen W, Linse R, Boettjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Heinz A, Hauschild A, Schaefer M.

J Immunother. 2011 May;34(4):403-8. doi: 10.1097/CJI.0b013e31821b7a4b.

PMID:
21499123
20.

Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma.

Wong SF, Jakowatz JG, Taheri R.

Ann Pharmacother. 2004 Oct;38(10):1655-9. Epub 2004 Aug 10.

PMID:
15304625

Supplemental Content

Support Center